The CureSearch Young Investigator International Award in Pediatric Cancer Drug Development supports early-career investigators transitioning to independence in pediatric oncology drug development. The program is designed to bridge the gap between postdoctoral training and full academic independence, with a focus on translational and preclinical research that can lead to new therapeutics for children with cancer. The 2026/27 cycle officially opened on March 2, 2026, and offers up to $75,000 per year for 3 years.
Eligibility Criteria:
- Applicants must hold an MD, PhD, or MD-PhD.
- Applicants must be no more than six years beyond completion of postdoctoral training.
- Applicants must hold an academic appointment at the Instructor or Assistant Professor level, or have a confirmed transition into such a position within the first year of funding.
- Applications are accepted from institutions in the US, South America, EU, UK, Japan, Canada, China, or Australia.
Funding Details:
- $75,000 USD per year for 3 years ($225,000 total).
- Up to four awards may be made, depending on funds and scientific merit.
- Earliest project start date: January 1, 2027.
Deadline:
- LOI deadline: April 14, 2026.
- LOI notification / invited full applications: May 11, 2026.
- Full application deadline: July 16, 2026.
Where to go for further information:
- Official RFA: CureSearch Young Investigator Award RFA PDF
- CureSearch RFAs page: CureSearch RFAs